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with median follow up of 18 months (6-40 months). Six 
patients had prior surgical resection of tumor, 12 received 
treatment as first line. The majority (60 %) of lesions were 
close to the optic pathway with median values for GTV 
volume was 9,4 cm3 (0,38-55,66 cm3). The control rates at 
tow years were favorable with stable disease in 100 % 
patients, vision was preserved and improved symptoms in 65% 
patients. We observed no grade 3 or 4 toxicity. The most 
frequent being grade 1 retro-orbital pain (20%). No late 
toxicity was reported and no death during the follow – up 
period.  
 
Conclusion: Robotic Hypo-fractionated stereotactic 
radiotherapy for Cavernous sinus meningioma is feasible and 
provides a satisfactory local control with acceptable 
tolerance, either as a first line treatment or as adjuvant to 
incomplete surgery or relapse. Although this type of tumor 
has a slow evolution, extended follow-up is mandatory.  
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Purpose or Objective: Until the advent of stereotactic 
radiotherapy, the main treatment option consisted of cranial 
radiation for palliation. With a more radical intent, and only 
in selected patients, surgical resection and adjuvant 
radiotherapy was indicated later. The purpose of this study is 
to evaluate the results obtained after treatment with single-
session radiosurgery. 
 
Material and Methods: Between 2002 and 2014, has collected 
a representative sample of 592 patients with histological 
diagnosis of brain metastases, of which 340 were men and 
252 women. The average age in this group was 55.67 years 
(14-82 years) and with a KPS of 90 in 58.3% of patients. The 
most common location of these was lung 51%, followed by 
17.1% mom. The most frequent pathological study 
adenocarcinoma was 23.5%, followed by squamous 10.6%. In 
most 63.2% no surgery was performed. The most common site 
was the frontal 24.4%. All patients were treated with 
radiosurgery (stereotactic radiotherapy) single session with a 
median dose of treatment of 18 Gy. 
 
Results: With a median follow-up of 7 months, median 
survival was 14.23 months in a range of 0-117 months. In 
terms of toxicity, only 3.5% of the presented radiation 
necrosis (21 patients), while the cerebral edema was 
reported in 10.8% (64 patients). 
 
Conclusion: The single session radiosurgery is a conservative 
but with a radical purpose, offering technical and few side 
effects is very convenient for the patient. 
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Purpose or Objective: To access treatment toxity and 
patients’ survival after Volumetric Modulated Arc Therapy, a 
novel rotational Intensity Modulated RadioTherapy (IMRT) 
technique, with Simultaneus in-field Boost (SIB) for patients 
with brain metastases. 
 
Material and Methods: Between November 2010 and March 
2015, 26 patients with 1-3 brain metastases were treated 
with SIB-IMRT in the Department of Radiation Oncology at V. 
Fazzi Hospital (maximum diameter of largest metastasis ≤ 3 
cm, KPS ≥ 70, RPA < III). Mean age was 61 ± 7.5 years. 
Patients were neurologically stable. Extracranial disease 
well-controlled (6-month estimated median life expectancy). 
Patients will undergo contrast-enhanced TC scan of the brain 
for radiotherapy planning purposes. The macroscopic (gross) 
tumor volume (GTV) was drawn on the MRI images. The 
prescription isodose line was generally 3 mm larger than the 
GTV. Patients will be treated with WBRT/SIB using VMAT, 
delivering a total of 30 Gy in 10 fractions to the whole brain 
and SIB doses to brain metastases were 40 Gy to lesions >or= 
2.0 cm and 50 Gy to lesions <2.0 cm in diameter, delivered 
once daily on working days. Following therapy completion, 
patients will be seen every 3 months for the 1st year, then 
every 6 months thereafter. Patients will have MRI brain at 3 
months and 1 year, and every 6 months after the first year. 
Any toxicity was recorded according to the RTOG. 
 
Results: The median follow-up interval was 9 months (range, 
2 months- 16 months). The median overall survival time was 
11 months, and 3 of patients died of disease progression. The 
6-month overall survival was 91%. After SIB-IMRT treatment 
of 42 brain lesions, 35 lesions demonstrated complete 
responses, 5 lesions demonstrated partial responses, 2 lesion 
demonstrated stable disease. Actuarial local tumor control 
rates at 6 months, 1 year and 2 years were 93.9, 82% and 
54%, respectively. Thirty-eight patients did not have any 
adverse events >grade1. The majority of common adverse 
events were grade 2 headaches (4 patients), grade 2 motor 
neuropathy (2 patients), and grade 2 lethargy (2 patient). 
One patient developed a grade 3 headache 5 months after 
receiving SIB-IMRT.  
 
Conclusion: The delivery of 40/50 Gy in 10 fractions to 1 - 3 
BM using VMAT provides a high level of tumor control with 
minimal toxicity. Therefore, we believe there is a need for a 
larger prospective study to establish dosing guidelines for SIB-
IMRT and to pave the way for a randomized trial to compare 
SRS/STS plus WBRT with this approach. 
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Purpose or Objective: To evaluate radiation techniques in 
the treatment of Hodgkin’s Lymphoma (HL) and Non-
Hodgkin’s Lymphoma (NHL) with mediastinal disease over 10-
year period, and the toxicity.  
 
Material and Methods: Between 2003-2015, 173 patients 
(pts) with stage I-III nodal lymphoma were treated in our 
institution: some of these patients were irradiated for HL or 
NHL with mediastinal disease. Some of the patients were 
treated by 3DCRT, others by IMRT 
 
Results: We studied 26 men and 43 women with a median 
age of 26 years. The median follow-up was 43 months. Forty 
nine pts were treated by 3DCRT and 20 pts-by IMRT. The 
median dose received by patients treated for NHL was 40 Gy 
(range: 36-44 Gy) and the median dose received by pts with 
HL was 30 Gy (range: 30-36 Gy). Between 2003-2006, 16 pts 
were treated by 3DCRT vs. 0 by IMRT. Between 2007-2009, 16 
pts received 3DCRT and 1-IMRT. Between 2010-2015, 19 pts 
received IMRT, and no patients 3DCRT. Eleven of the 20 
patients (55%) treated by IMRT and 35/49 pts (71.4%) treated 
by 3DCRT experienced acute toxicity. Among the patients 
treated by 3DCRT, 1 patient experienced grade 1 radiation 
pneumonitis and 2 patients experienced grade 1 acute 
mucositis. No late toxicity was observed in the patients 
treated by IMRT. 
 
Conclusion: Improvement of radiation techniques for HL and 
NHL appears to have improved acute and late clinical safety. 
Longer follow-up is necessary to evaluate very late toxicity. 
 
